Prostate Cancer: Advances in Radiation Oncology, Molecular Biology, and Future Treatment Strategies
Sokoloff, Mitchell H.
FitzGerald, Thomas J.
Document TypeBook Chapter
Keywordsclinical process improvement for prostate cancer
modern care for the prostate patient
patient outcome in prostate cancer
radiation therapy for prostate cancer
treatment strategies for prostate cancer
MetadataShow full item record
AbstractProstate cancer remains an important health problem worldwide affecting one in every six men including members of vulnerable communities. Although successful treatments have been delivered to men affected with the disease resulting in improved patient outcome, process improvements including therapy titration and augmentation are needed to optimize tumor control and limit normal tissue injury from therapy. In this chapter, we describe current management strategies for optimal patient care with radiation therapy and opportunities for improvement of care moving forward with applied science to apply therapy in a strategic manner, potentially improving care and outcome for patients treated for this disease.
SourceWang T, Lewis B, Ruscetti M, Mittal K, Wang MJ, Sokoloff M, Ding L, Bishop-Jodoin M, FitzGerald TJ. Prostate Cancer: Advances in Radiation Oncology, Molecular Biology, and Future Treatment Strategies. In: Barber N, Ali A, editors. Urologic Cancers [Internet]. Brisbane (AU): Exon Publications; 2022 Sep 12. Chapter 13. PMID: 36343136.
Permanent Link to this Itemhttp://hdl.handle.net/20.500.14038/51356
RightsCopyright: The Authors. The authors confirm that the materials included in this chapter do not violate copyright laws. Where relevant, appropriate permissions have been obtained from the original copyright holder(s), and all original sources have been appropriately acknowledged or referenced. Licence: This open access article is licenced under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) https://creativecommons.org/licenses/by-nc/4.0/; Attribution-NonCommercial 4.0 International
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as Copyright: The Authors. The authors confirm that the materials included in this chapter do not violate copyright laws. Where relevant, appropriate permissions have been obtained from the original copyright holder(s), and all original sources have been appropriately acknowledged or referenced. Licence: This open access article is licenced under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) https://creativecommons.org/licenses/by-nc/4.0/
Showing items related by title, author, creator and subject.
PTEN loss in biopsy tissue predicts poor clinical outcomes in prostate cancerMithal, Prabhakar; Allott, Emma; Gerber, Leah; Reid, Julia; Welbourn, William; Tikishvili, Eliso; Park, Jimmy; Younus, Adib; Sangale, Zaina; Lanchbury, Jerry S.; et al. (2014-12-01)OBJECTIVES: To determine whether PTEN status in prostate biopsy represents a predictor of intermediate and long-term oncological outcomes after radical prostatectomy, and whether PTEN status predicts response to androgen deprivation therapy. METHODS: In a retrospective analysis of 77 men treated by radical prostatectomy who underwent diagnostic biopsy between 1992-2006, biopsy samples were stained for PTEN expression by the PREZEON assay with > 10% staining reported as positive. Cox proportional hazards and log-rank models were used to assess the correlation between PTEN loss and clinical outcomes. RESULTS: During a median follow-up period after radical prostatectomy of 8.8 years, 39 men (51%) developed biochemical recurrence, four (5%) had castration-resistant prostate cancer, two (3%) had metastasis and two (3%) died from prostate cancer. PTEN loss was not significantly associated with biochemical recurrence (hazard ratio 2.1, 95% confidence interval 0.9-5.1, P = 0.10), but significantly predicted increased risk of castration-resistant prostate cancer, metastasis and prostate cancer-specific mortality (all log-rank, P < 0.0001), and time from androgen deprivation therapy to castration-resistant prostate cancer (log-rank, P = 0.003). No patient without PTEN loss developed metastases or died from prostate cancer. CONCLUSIONS: PTEN loss at the time of biopsy seems to predict time to development of metastasis, prostate cancer-specific mortality and, for the first time, castration-resistant prostate cancer and response to androgen deprivation therapy after radical prostatectomy. If confirmed by larger studies, this would support the use of PTEN loss as an early marker of aggressive prostate cancer.
UMass PCORI PSA decision aid [English]Saver, Barry G.; Bacigalupe, Gonzalo; Esparza, Nancy; Cutrona, Sarah L.; Hayes, Marcela; Gorodetsky, Tatyana; Mazor, Kathleen M.; Calista, Joanne; Luckmann, Roger S. (2015-06-10)This is a presentation developed as a decision aid to help consumers understand the May 2012 recommendations of the US Preventive Services Task Force against routine prostate cancer (PSA) screening and why that might be the right choice for them. This decision aid was produced in 2013-2014 under research contract 1IP2PI000633 from the Patient-Centered Outcomes Research Institute (PCORI) to the University of Massachusetts Medical School by personnel from: The University of Massachusetts Medical School, the University of Massachusetts Boston, and the Central Massachusetts Area Health Education Center.
Methylation of SRD5A2 promoter predicts a better outcome for castration-resistant prostate cancer patients undergoing androgen deprivation therapyWang, Zongwei; Deng, Tuo; Long, Xingbo; Lin, Xueming; Wu, Shulin; Wang, Hongbo; Ge, Rongbin; Zhang, Zhenwei; Wu, Chin-Lee; Taplin, Mary-Ellen; et al. (2020-03-05)PURPOSE: To determine whether SRD5A2 promoter methylation is associated with cancer progression during androgen deprivation therapy (ADT) in CRPC. PATIENTS AND METHODS: In a Local CRPC cohort, 42 prostatic specimens were collected from patients who were diagnosed as CRPC and underwent transurethral resection of the prostate (TURP) at Massachusetts General Hospital (MGH). In a metastatic CRPC (Met CRPC) cohort, 12 metastatic biopsies were collected from CRPC patients who would be treated with abiraterone plus dutasteride (Clinical Trial NCT01393730). As controls, 36 benign prostatic specimens were collected from patients undergoing prostate reduction surgery for symptoms of bladder outlet obstruction secondary to benign prostatic hyperplasia (BPH). The methylation status of cytosine-phosphate-guanine (CpG) site(s) at SRD5A2 promoter regions was tested. RESULTS: Compared with benign prostatic tissue, CRPC samples demonstrated higher SRD5A2 methylation in the whole promoter region (Local CRPC cohort: P < 0.001; Met CRPC cohort: P < 0.05). In Local CRPC cohort, a higher ratio of methylation was correlated with better OS (R2 = 0.33, P = 0.013). Hypermethylation of specific regions (nucleotides -434 to -4 [CpG# -39 to CpG# -2]) was associated with a better OS (11.3+/-5.8 vs 6.4+/-4.4 years, P = 0.001) and PFS (8.4+/-5.4 vs 4.5+/-3.9 years, P = 0.003) with cutoff value of 37.9%. Multivariate analysis showed that SRD5A2 methylation was associated with OS independently (whole promoter region: P = 0.035; specific region: P = 0.02). CONCLUSION: Our study demonstrate that SRD5A2 methylation in promoter regions, specifically at CpG# -39 to -2, is significantly associated with better survival for CRPC patients treated with ADT. Recognition of epigenetic modifications of SRD5A2 may affect the choices and sequence of available therapies for management of CRPC.